Want to see PHAT full AI Analyst Report?
PHAT Stock Chart & Stats
$11.44
$0.51(4.46%)
At close: 4:00 PM EDT
$11.44
$0.51(4.46%)
Day’s Range― - ―
52-Week Range$8.21 - $18.31
Previous Close$11.95
Volume664.73K
Average Volume (3M)1.03M
Market Cap
$748.33M
Enterprise Value$1.28K
Total Cash (Recent Filing)$182.48M
Total Debt (Recent Filing)$167.11M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Nov 05, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding80,900,930
10 Day Avg. Volume935,742
30 Day Avg. Volume1,029,809
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-2.76
Price to Sales (P/S)6.91
P/FCF Ratio-7.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.83Price Target Upside82.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$327.93M
Bulls Say, Bears Say
Bulls Say
Revenue And Prescription GrowthRapid revenue and prescription growth indicates increasing adoption of VOQUEZNA. Continued expansion in covered prescriptions can broaden the commercial base and support sustained top-line growth over the next several quarters.
Operating LeverageExpense discipline alongside strong sales growth demonstrates improving operating leverage. Reaching ex-stock-compensation profitability ahead of guidance suggests the commercial platform may scale with better margin efficiency as revenue expands.
Clinical Pipeline And LiquidityA progressing EoE program and planned Phase 3 GERD trial provide opportunities to expand VOQUEZNA's addressable market. The cash balance supports development and commercialization, reducing near-term financing dependence.
Bears Say
Persistent Losses And Cash BurnDespite recent improvement, substantial operating losses and negative cash flow show that the business has not yet achieved durable self-funding. Negative equity further limits financial flexibility and increases execution risk.
Access And Reimbursement FrictionHigh discounts, prior-authorization hurdles, and cash-pay reliance can limit prescription conversion and reduce realized revenue. These access issues may persist as adoption broadens, constraining commercial efficiency and margins.
Near-Term Investment And Competitive RiskPlanned marketing and clinical spending will delay durable cash-flow positivity until 2027, while competing PCAB data could affect prescribing perceptions. Together, these factors raise the investment required to sustain growth.
Phathom Pharmaceuticals News
PHAT FAQ
What was Phathom Pharmaceuticals, Inc.’s price range in the past 12 months?
Phathom Pharmaceuticals, Inc. lowest stock price was $8.21 and its highest was $18.31 in the past 12 months.
What is Phathom Pharmaceuticals, Inc.’s market cap?
Phathom Pharmaceuticals, Inc.’s market cap is $748.33M.
When is Phathom Pharmaceuticals, Inc.’s upcoming earnings report date?
Phathom Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 76 days.
How were Phathom Pharmaceuticals, Inc.’s earnings last quarter?
Phathom Pharmaceuticals, Inc. released its earnings results on Jul 30, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.176 by -$0.034.
Is Phathom Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Phathom Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Phathom Pharmaceuticals, Inc. pay dividends?
Phathom Pharmaceuticals, Inc. does not currently pay dividends.
What is Phathom Pharmaceuticals, Inc.’s EPS estimate?
Phathom Pharmaceuticals, Inc.’s EPS estimate is -0.06.
How many shares outstanding does Phathom Pharmaceuticals, Inc. have?
Phathom Pharmaceuticals, Inc. has 80,900,930 shares outstanding.
What happened to Phathom Pharmaceuticals, Inc.’s price movement after its last earnings report?
Phathom Pharmaceuticals, Inc. reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.176. Following the earnings report the stock price went down -22.423%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in PHAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phathom Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.83 (82.11% Upside)
$20.83 (82.11% Upside)
Blogger Sentiment
Bullish
PHAT Sentiment 75%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 425.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
30.71%
Trailing 12-Months
Company Description
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
PHAT Company Deck
PHAT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational progress: sharply higher revenue (+88% YoY), disciplined expense reductions (-34% YoY in cash operating expenses), first-time operating profitability excluding stock comp, first positive cash from operations and healthy cash balance. Clinical programs (EoE Phase 2 enrollment complete; Phase 3 as-needed GERD to start Q4) and updated guidance support continued growth. Key near-term challenges are physician/payer workflow friction limiting broader adoption, a high gross-to-net discount (55%–59%) that may moderate realized revenue, a meaningful cash-pay portion of scripts (~36% in Q2), and planned back-half investments that will consume cash before anticipated durable cash flow positivity in 2027. Overall, the positives (revenue acceleration, profitability milestone, clinical progress, and liquidity) materially outweigh the listed near-term obstacles.View all PHAT earnings summariesPHAT Stock 12 Month Forecast
Average Price Target
$20.83
▲(82.11% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Urogen Pharma
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
8.89% Insiders
13.06% Mutual Funds
48.90% Other Institutional Investors
19.94% Public Companies and
Individual Investors